Literature DB >> 24876106

Molecular imaging with bioluminescence and PET reveals viral oncolysis kinetics and tumor viability.

Darshini Kuruppu1, Anna-Liisa Brownell2, Khalid Shah2, Umar Mahmood2, Kenneth K Tanabe1.   

Abstract

Viral oncolysis, the destruction of cancer cells by replicating virus, is an experimental cancer therapy that continues to be explored. The treatment paradigm for this therapy involves successive waves of lytic replication in cancer cells. At present, monitoring viral titer at sites of replication requires biopsy. However, repeat serial biopsies are not practically feasible for temporal monitoring of viral replication and tumor response in patients. Molecular imaging provides a noninvasive method to identify intracellular viral gene expression in real time. We imaged viral oncolysis and tumor response to oncolysis sequentially with bioluminescence and positron emission tomography (PET), revealing the kinetics of both processes in tumor xenografts. We demonstrate that virus replication cycles can be identified as successive waves of reporter expression that occur ∼2 days after the initial viral tumor infection peak. These waves correspond to virions that are released following a replication cycle. The viral and cellular kinetics were imaged with Fluc and Rluc bioluminescence reporters plus two 18F-labeled PET reporters FHBG [9-(4-18F-fluoro-3-[hydroxymethyl] butyl) guanine] and FLT (18F-3'-deoxy-3-'fluorothymidine), respectively. Correlative immunohistochemistry on tumor xenograft sections confirmed in vivo results. Our findings show how PET can be used to identify virus replication cycles and for real-time measurements of intratumoral replicating virus levels. This noninvasive imaging approach has potential utility for monitoring viral oncolysis therapy in patients. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2014        PMID: 24876106      PMCID: PMC4147034          DOI: 10.1158/0008-5472.CAN-13-3472

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

Review 1.  Viral oncolysis.

Authors:  John T Mullen; Kenneth K Tanabe
Journal:  Oncologist       Date:  2002

2.  An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma.

Authors:  S S Yoon; H Nakamura; N M Carroll; B P Bode; E A Chiocca; K K Tanabe
Journal:  FASEB J       Date:  2000-02       Impact factor: 5.191

3.  Optical imaging of Renilla luciferase reporter gene expression in living mice.

Authors:  S Bhaumik; S S Gambhir
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

4.  Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant.

Authors:  D J Goldstein; S K Weller
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

Review 5.  Oncolytic viruses.

Authors:  E Antonio Chiocca
Journal:  Nat Rev Cancer       Date:  2002-12       Impact factor: 60.716

6.  Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression.

Authors:  Juri Gelovani Tjuvajev; Mikhail Doubrovin; Timothy Akhurst; Shangde Cai; Julius Balatoni; Mian M Alauddin; Ronald Finn; William Bornmann; Howard Thaler; Peter S Conti; Ronald G Blasberg
Journal:  J Nucl Med       Date:  2002-08       Impact factor: 10.057

7.  Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus.

Authors:  N M Carroll; E A Chiocca; K Takahashi; K K Tanabe
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

8.  Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen.

Authors:  Hideki Kasuya; Timothy M Pawlik; John T Mullen; James M Donahue; Hideo Nakamura; Soundararajalu Chandrasekhar; Hiroshi Kawasaki; Enid Choi; Kenneth K Tanabe
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

9.  Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo.

Authors:  Khalid Shah; Yi Tang; Xandra Breakefield; Ralph Weissleder
Journal:  Oncogene       Date:  2003-10-09       Impact factor: 9.867

10.  Imaging characteristics, tissue distribution, and spread of a novel oncolytic vaccinia virus carrying the human sodium iodide symporter.

Authors:  Dana Haddad; Chun-Hao Chen; Sean Carlin; Gerd Silberhumer; Nanhai G Chen; Qian Zhang; Valerie Longo; Susanne G Carpenter; Arjun Mittra; Joshua Carson; Joyce Au; Mithat Gonen; Pat B Zanzonico; Aladar A Szalay; Yuman Fong
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

View more
  5 in total

Review 1.  Trial Watch-Oncolytic viruses and cancer therapy.

Authors:  Jonathan Pol; Aitziber Buqué; Fernando Aranda; Norma Bloy; Isabelle Cremer; Alexander Eggermont; Philippe Erbs; Jitka Fucikova; Jérôme Galon; Jean-Marc Limacher; Xavier Preville; Catherine Sautès-Fridman; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

2.  HSV-1 as a novel therapy for breast cancer meningeal metastases.

Authors:  D Kuruppu; K K Tanabe
Journal:  Cancer Gene Ther       Date:  2015-09-18       Impact factor: 5.987

3.  A bright future for bioluminescent imaging in viral research.

Authors:  Stewart M Coleman; Alistair McGregor
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

Review 4.  Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice.

Authors:  Omeed Moaven; Christopher W Mangieri; John A Stauffer; Panos Z Anastasiadis; Mitesh J Borad
Journal:  JCO Precis Oncol       Date:  2021-02-24

Review 5.  Chemiluminescence and Bioluminescence Imaging for Biosensing and Therapy: In Vitro and In Vivo Perspectives.

Authors:  Yongcun Yan; Pengfei Shi; Weiling Song; Sai Bi
Journal:  Theranostics       Date:  2019-05-31       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.